<DOC>
	<DOC>NCT00568529</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and overall survival of the regimen of XELOX (Xeloda and oxaliplatin combination) in the patients with relapsed and refractory gastric cancer.</brief_summary>
	<brief_title>Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer</brief_title>
	<detailed_description>The result of treatment in relapsed and refractory gastric cancer is still not satisfactory. For the moment, the combination of 5-Fu and cisplatin is regularly used. Capecitabine and Oxaliplatin are new generation drugs of 5-Fu and cisplatin. The current study is to evaluate the efficacy and toxicity of this combination.</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age between 18 and 70 years Patients with histologically confirmed, unresectable, recurrent and/or metastatic gastric adenocarcinoma ECOG performance status ≤1 Measurable diseases according to the RECIST Relapse or refractory after the firstline chemotherapy Sign ICF,normal laboratory findings:absolute neutrophil count and platelet count ≥ 2.0×109/L and 80×109/L, respectively, hepatic function (total serum bilirubin ≤ UNL, transaminases ≤ 1.5 times upper normal limit) and renal function (calculated creatinine clearance ≥ 60 ml/min). Relapse within 6 months after adjuvant chemotherapy which contained oxaliplatin Have used any of drugs in the regimen in firstline chemotherapy Pregnant or lactating women,serious uncontrolled diseases and intercurrent infection The evidence of CNS metastasis History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix Received other chemotherapy regimen after metastasis Participated in other clinical trials.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Advanced gastric cancer</keyword>
	<keyword>Response rate</keyword>
	<keyword>Side effects</keyword>
	<keyword>time to progression</keyword>
	<keyword>overall survival</keyword>
</DOC>